A detailed history of Auxier Asset Management transactions in Biogen Inc. stock. As of the latest transaction made, Auxier Asset Management holds 16,182 shares of BIIB stock, worth $2.59 Million. This represents 0.47% of its overall portfolio holdings.

Number of Shares
16,182
Previous 16,220 0.23%
Holding current value
$2.59 Million
Previous $3.76 Million 16.6%
% of portfolio
0.47%
Previous 0.6%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$189.07 - $236.8 $7,184 - $8,998
-38 Reduced 0.23%
16,182 $3.14 Million
Q2 2024

Aug 13, 2024

SELL
$190.52 - $236.72 $73,350 - $91,137
-385 Reduced 2.32%
16,220 $3.76 Million
Q1 2024

May 08, 2024

SELL
$212.02 - $267.71 $1.07 Million - $1.35 Million
-5,053 Reduced 23.33%
16,605 $3.58 Million
Q4 2023

Feb 22, 2024

SELL
$222.59 - $267.94 $22,704 - $27,329
-102 Reduced 0.47%
21,658 $5.6 Million
Q3 2023

Nov 21, 2023

SELL
$253.3 - $285.89 $6,332 - $7,147
-25 Reduced 0.11%
21,760 $5.59 Million
Q2 2023

Aug 17, 2023

SELL
$275.25 - $318.06 $140,377 - $162,210
-510 Reduced 2.29%
21,785 $6.21 Million
Q1 2023

May 15, 2023

SELL
$256.56 - $292.34 $12,828 - $14,616
-50 Reduced 0.22%
22,295 $6.2 Million
Q4 2022

Feb 17, 2023

SELL
$252.44 - $306.72 $342,056 - $415,605
-1,355 Reduced 5.72%
22,345 $6.19 Million
Q3 2022

Nov 15, 2022

SELL
$194.69 - $268.46 $7,787 - $10,738
-40 Reduced 0.17%
23,700 $6.33 Million
Q2 2022

Aug 11, 2022

SELL
$187.54 - $223.02 $13,127 - $15,611
-70 Reduced 0.29%
23,740 $4.84 Million
Q4 2021

Mar 01, 2022

SELL
$223.92 - $287.77 $39,186 - $50,359
-175 Reduced 0.73%
23,810 $5.71 Million
Q3 2021

Nov 18, 2021

SELL
$282.99 - $369.05 $41,033 - $53,512
-145 Reduced 0.6%
23,985 $6.79 Million
Q2 2021

Aug 18, 2021

SELL
$259.0 - $414.71 $61,383 - $98,286
-237 Reduced 0.97%
24,130 $8.36 Million
Q1 2021

May 17, 2021

SELL
$242.95 - $284.63 $4,859 - $5,692
-20 Reduced 0.08%
24,367 $6.82 Million
Q4 2020

Mar 05, 2021

BUY
$236.26 - $355.63 $28,351 - $42,675
120 Added 0.49%
24,387 $5.97 Million
Q3 2020

Mar 05, 2021

SELL
$264.77 - $305.71 $11,914 - $13,756
-45 Reduced 0.19%
24,267 $6.88 Million
Q2 2020

Aug 20, 2020

SELL
$258.66 - $342.55 $504,387 - $667,972
-1,950 Reduced 7.43%
24,312 $6.51 Million
Q1 2020

May 15, 2020

SELL
$268.85 - $341.04 $310,521 - $393,901
-1,155 Reduced 4.21%
26,262 $8.31 Million
Q3 2019

Nov 15, 2019

BUY
$217.44 - $243.88 $43,488 - $48,776
200 Added 0.73%
27,417 $6.38 Million
Q2 2019

Aug 15, 2019

BUY
$219.29 - $241.72 $210,518 - $232,051
960 Added 3.66%
27,217 $6.37 Million
Q1 2019

May 14, 2019

BUY
$216.71 - $338.96 $21,671 - $33,896
100 Added 0.38%
26,257 $6.21 Million
Q4 2018

Feb 13, 2019

SELL
$278.5 - $352.75 $557,000 - $705,500
-2,000 Reduced 7.1%
26,157 $7.87 Million
Q2 2018

Aug 15, 2018

SELL
$257.52 - $306.91 $17,511 - $20,869
-68 Reduced 0.24%
28,157 $8.17 Million
Q1 2018

May 14, 2018

BUY
$260.13 - $367.91 $18,209 - $25,753
70 Added 0.25%
28,225 $7.73 Million
Q4 2017

Feb 14, 2018

BUY
$307.64 - $344.58 $3,076 - $3,445
10 Added 0.04%
28,155 $8.97 Million
Q3 2017

Nov 09, 2017

SELL
$281.15 - $329.69 $7,028 - $8,242
-25 Reduced 0.09%
28,145 $8.81 Million
Q2 2017

Aug 16, 2017

BUY
N/A
28,170
28,170 $7.64 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $23B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Auxier Asset Management Portfolio

Follow Auxier Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Auxier Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Auxier Asset Management with notifications on news.